Sustained, Long-Term Maintenance of Remission with Single-Agent Veliparib in Recurrent Triple-Negative Breast Cancer

Triple-negative breast cancers (TNBC) have poorer outcomes than hormone positive or human epidermal growth factor receptor 2 (HER2)-positive breast cancers, with chemotherapy being the usual standard of care. Veliparib, a poly ADP-ribose polymerase (PARP) inhibitor, has been studied in both breast c...

Descripción completa

Detalles Bibliográficos
Autores principales: Kota, Karthik, Puhalla, Shannon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5580965/
https://www.ncbi.nlm.nih.gov/pubmed/28875097
http://dx.doi.org/10.7759/cureus.1424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5580965/
https://www.ncbi.nlm.nih.gov/pubmed/28875097
http://dx.doi.org/10.7759/cureus.1424

Ejemplares similares